| Levocarnitine for Dry Eye in Sjogren's Syndrome (NCT03953703) | Vanderbilt University Medical Center | 2021-11-17 |
| Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study (NCT04884217) | PharmaDax Inc. | 2021-05-20 |
| Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye (NCT04493658) | Johns Hopkins University | 2021-01-11 |
| Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting (NCT04649177) | Boston Sight | 2020-12-15 |
| A Randomized Study of Smile Exercise for Dry Eye (NCT04421300) | Zhongshan Ophthalmic Center, Sun Yat-sen University | 2020-07-02 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome (NCT04147650) | Aurinia Pharmaceuticals Inc. | 2019-10-14 |
| Tavilermide Ophthalmic Solution for the Treatment of Dry Eye (NCT03925727) | Mimetogen Pharmaceuticals USA, Inc. | 2019-03-28 |
| Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease (NCT03408015) | University of Alabama at Birmingham | 2019-01-01 |
| Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops (NCT03706443) | Ohio State University | 2018-12-05 |
| Repository Corticotropin Injection in Keratoconjunctivitis Sicca (NCT03398018) | University of Alabama at Birmingham | 2018-11-01 |
| Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye (NCT03436576) | Pontificia Universidad Catolica de Chile | 2018-09-12 |
| Tear Production by Nasal Neurostimulation Compared to Active Control (NCT02970799) | Oculeve, Inc. | 2016-08-31 |
| An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca (NCT02845674) | Sun Pharmaceutical Industries Limited | 2016-07-29 |
| Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator (NCT02798289) | Oculeve, Inc. | 2016-06-01 |
| Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (NCT02813265) | Kala Pharmaceuticals, Inc. | 2016-06-01 |
| Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (NCT02819284) | Kala Pharmaceuticals, Inc. | 2016-06-01 |
| Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca (NCT02688556) | Sun Pharmaceutical Industries Limited | 2016-02-01 |
| A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome (NCT02680158) | Oculeve, Inc. | 2016-01-31 |
| A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease (NCT02665234) | Mimetogen Pharmaceuticals USA, Inc. | 2016-01-01 |
| A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye (NCT02634853) | Mimetogen Pharmaceuticals USA, Inc. | 2015-12-01 |
| Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator (NCT02526290) | Oculeve, Inc. | 2015-08-31 |
| Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca (NCT02254265) | Sun Pharmaceutical Industries Limited | 2014-09-01 |
| Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (NCT02188160) | Kala Pharmaceuticals, Inc. | 2014-06-01 |
| A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye (NCT02117687) | Allergan | 2014-05-14 |
| Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome (NCT02066896) | Federal University of São Paulo | 2014-05-01 |
| A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome (NCT02139033) | Ocusoft, Inc. | 2014-05-01 |
| A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) (NCT02121301) | Mitotech, SA | 2014-04-01 |
| To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (NCT01900249) | Rigel Pharmaceuticals | 2013-07-01 |
| Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) (NCT01817582) | Bausch & Lomb Incorporated | 2013-05-17 |
| Ocular Manifestations in Rheumatic Diseases (NCT03753893) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2013-05-01 |
| Effects of Dry Eye Treatments on the Ocular Surface (NCT01797822) | Baylor College of Medicine | 2013-02-01 |
| A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease (NCT01733992) | Rigel Pharmaceuticals | 2012-11-01 |
| Effect of Controlled Adverse Environment (CAE) on Tear Film Stability (NCT01547936) | ORA, Inc. | 2012-02-01 |
| Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1) (NCT01421498) | Shire | 2011-08-29 |
| Trial of CF101 to Treat Patients With Dry Eye Disease (NCT01235234) | Can-Fite BioPharma | 2011-07-01 |
| A Study Of Tasocitinib In Dry Eye Subjects (NCT01226680) | Pfizer | 2010-12-01 |
| Omega-3 Fatty Acid Supplements and Dry Eye (NCT01213342) | Ohio State University | 2010-05-01 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea (NCT01057147) | Kubota Vision Inc. | 2010-02-01 |
| Dry Eye Assessment and Management: Feasibility Study (NCT01102257) | Asbell, Penny, M.D. | 2010-01-01 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye (NCT01027013) | Kubota Vision Inc. | 2009-12-01 |
| Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye (NCT00987727) | Allergan | 2009-11-01 |
| TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease (NCT00848198) | TearLab Corporation | 2009-02-01 |
| A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) (NCT00851734) | Lux Biosciences, Inc. | 2009-02-01 |
| Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome (NCT00788229) | Dhp Korea Co., Ltd. | 2008-11-01 |
| Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye (NCT00883649) | Virginia Eye Consultants | 2008-09-01 |
| Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK (NCT00411827) | Walter Reed National Military Medical Center | 2008-01-01 |
| Acupuncture Treatment of Dry Eye (NCT00554879) | Walter Reed Army Medical Center | 2007-11-01 |
| Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome (NCT00426543) | University of Copenhagen | 2007-01-01 |
| Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca (NCT00349466) | Can-Fite BioPharma | 2007-01-01 |
| Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis (NCT00407043) | Ophthalmic Consultants of Long Island | 2006-11-01 |
| Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca (NCT00128245) | Novartis | 2004-09-01 |
| Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease (NCT00717418) | Allergan | 2004-09-01 |
| Study of Rebamipide Eye Drops to Treat Dry Eye (NCT00201955) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-05-01 |
| Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye (NCT00037661) | Merck Sharp & Dohme LLC | 2002-04-01 |
| Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome (NCT00025818) | Allergan | 2001-05-01 |
| Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops (NCT00001731) | National Eye Institute (NEI) | 1997-11-01 |